New treatment for muscular dystrophies based on the administration of boron or a compound of boron.
The active compound can be also used in combination with another active principle or with another current therapy (“Combination therapy”).
The active compound may be administered with an excipient, carrier, and vehicle, commonly used in the pharmacology field, including biodegradable polymeric materials.
The pharmaceutical composition may be administered orally, parenterally, by inhalation spray, or rectally.
In vitro cellular studies presented similar positive results after addition of boron compound in two different muscular dystrophies, with extremely diverse aetiological origin (DMD and DM1).
In vivo studies showed the repair of muscle atrophy to physiologically healthy levels and also an extension of the life expectancy.
Competitive advantages: The active compound occurs naturally as a mineral o can be prepared easily.
The therapeutic effects of boron are expandable and embracing several muscular dystrophies. Boron treatment cannot only allow muscle regeneration at the anatomical level but also at a functional level.
To be determined
Patient need addressed: muscular dystrophies
Spanish patent application P201830905, International patent PCT to be applied
Licensing or Assignment
INVENTOR / TEAM
Patricia Rico, Manuel Salmerón, Ruben Artero, Ariadna Bargiela, Manuel Perez